News from biohaven pharmaceutical holding company ltd. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 23, 2022, 07:30 ET US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for ...

May 23, 2022, 07:15 ET Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and...

May 10, 2022, 06:50 ET Biohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments

Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. today announced that the companies have entered into a definitive agreement under which...

May 09, 2022, 07:30 ET Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

Apr 14, 2022, 16:30 ET Biohaven Real-World Study Highlights Increased Healthcare Utilization Among Americans with Episodic Migraine having Higher Levels of Migraine-Related Disability

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced the publication of new real-world research showing that as migraine-related...

Apr 14, 2022, 07:30 ET Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced two updates regarding Nurtec® ODT (rimegepant), the only FDA-approved...

Apr 07, 2022, 07:30 ET Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis

Longitudinal medical and prescription claims were used to assess opioid prescriptions and MME's dispensed amongst migraine patients nine months prior ...

Apr 06, 2022, 07:30 ET Biohaven Expands Commitment to Supporting Veterans and Military Through Sole Sponsorship of National Headache Foundation's (NHF) Outreach Program

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it is the sole sponsor of the National Headache Foundation's (NHF)...

Apr 01, 2022, 07:30 ET Nurtec (rimegepant) Lactation Clinical Study Published in Breastfeeding Medicine Journal

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that data from a Phase 1, single-center, open-label study evaluating the...

Mar 31, 2022, 07:30 ET Biohaven Data at 2022 American Academy of Neurology (AAN) Annual Meeting Demonstrate Leadership in Migraine and Commitment to Advancing Potential New Therapeutic Options in Neurological Diseases

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 13 abstracts, including two oral presentations, will be featured at...

Feb 25, 2022, 07:00 ET BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates...

Feb 25, 2022, 06:59 ET Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for...

Feb 25, 2022, 06:55 ET Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") announced today that it has entered into a definitive...

Feb 25, 2022, 06:50 ET Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that it entered into a worldwide license agreement with...

Feb 22, 2022, 07:30 ET Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

Feb 16, 2022, 07:30 ET BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

Feb 14, 2022, 07:00 ET Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced positive top-line results from an...

Feb 12, 2022, 12:00 ET Hardware LDN Debuts Fall/Winter 2022 Collection

Heating up the runway this winter, Jessica Horwell makes a return to New York Fashion Week, captivating the city with her signature execution of sexy ...

Feb 03, 2022, 07:30 ET NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced the publication of new findings from its long-term safety study showing...

Jan 25, 2022, 07:30 ET Biohaven's Nurtec® ODT Extends Partnership with Rick Ware Racing for 2022 NASCAR Cup Series and NTT INDYCAR Series

Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) extends its sponsorship for the second year as the primary partner ...

Jan 10, 2022, 00:01 ET Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain

Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven,...

Jan 06, 2022, 07:00 ET BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT, MARKET LEADING NOVEL MIGRAINE THERAPY

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, ...

Jan 05, 2022, 07:00 ET Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have completed the...

Dec 13, 2021, 07:00 ET BIOHAVEN ANNOUNCES NURTEC® ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE U.S. FOR PREVENTION OF MIGRAINE

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that NURTEC ODT (rimegepant) 75 mg was approved by the...

Dec 06, 2021, 07:30 ET Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results from the second pivotal clinical trial...